These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience. Schwarz MD; Li M; Tsao J; Zhou R; Wu YW; Sankar R; Wu JY; Hussain SA Epilepsy Behav; 2016 Apr; 57(Pt A):29-33. PubMed ID: 26921595 [TBL] [Abstract][Full Text] [Related]
5. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Sergott RC; Westall CA Acta Neurol Scand Suppl; 2011; (192):48-56. PubMed ID: 22061180 [TBL] [Abstract][Full Text] [Related]
7. Balancing clinical benefits of vigabatrin with its associated risk of vision loss. Pellock JM Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183 [TBL] [Abstract][Full Text] [Related]
8. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Tolman JA; Faulkner MA Expert Opin Pharmacother; 2009 Dec; 10(18):3077-89. PubMed ID: 19954276 [TBL] [Abstract][Full Text] [Related]
9. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures. Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566 [TBL] [Abstract][Full Text] [Related]
12. The role of vigabatrin in childhood seizure disorders: results from a clinical audit. Prasad AN; Penney S; Buckley DJ Epilepsia; 2001 Jan; 42(1):54-61. PubMed ID: 11207785 [TBL] [Abstract][Full Text] [Related]
13. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. Wild JM; Chiron C; Ahn H; Baulac M; Bursztyn J; Gandolfo E; Goldberg I; Goñi FJ; Mercier F; Nordmann JP; Safran AB; Schiefer U; Perucca E CNS Drugs; 2009 Nov; 23(11):965-82. PubMed ID: 19845417 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215 [TBL] [Abstract][Full Text] [Related]
15. Visual field constriction on vigabatrin. Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799 [TBL] [Abstract][Full Text] [Related]
16. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Paul SR; Krauss GL; Miller NR; Medura MT; Miller TA; Johnson MA Epilepsia; 2001 Apr; 42(4):525-30. PubMed ID: 11440348 [TBL] [Abstract][Full Text] [Related]
17. [Epilepsy and Sabril]. Depasse F Bull Soc Belge Ophtalmol; 2007; (304):33-40. PubMed ID: 17718226 [TBL] [Abstract][Full Text] [Related]
20. A risk-benefit assessment of treatments for infantile spasms. Nabbout R Drug Saf; 2001; 24(11):813-28. PubMed ID: 11665869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]